Skip directly to content

Topic Collection: Transcatheter or surgical Aortic valve replacement

Viernes, Juinio 12, 2020

Letter from the Editor
In the past decade, there has been a powerful shift toward the use of transcatheter aortic valve replacement (TAVR) for patients with severe symptomatic aortic stenosis. Unlike almost all other therapies for valvular heart disease, TAVR has been rigorously evaluated in randomized clinical trials against the standard of care — surgical aortic valve replacement (SAVR) — and has been shown to be at least equivalent to, if not better than, SAVR in certain patient populations and across the spectrum of surgical risk from inoperable to, most recently, low-surgical-risk patients.

 


NEJM Journal Watch summary, reutilizado con permiso del Grupo NEJM.

 

Código de aprobación: PP-UMC-CHL-0028